Sunshine Biopharma Announces Reverse Stock Split to Maintain NASDAQ ListingAccesswire · 2 days ago
Sunshine Biopharma, Inc. (NASDAQ:SBFM) Sees Significant Growth in Short InterestDefense World · Oct 12, 2026
Sunshine Biopharma Announces Closing of up to $20.4 Million Public OfferingAccesswire · Oct 9, 2026
Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public OfferingAccesswire · Oct 8, 2026
Sunshine Biopharma, Inc. (SBFM) Upgraded to Buy: Here's What You Should KnowZacks Investment Research · Sep 24, 2026
Sunshine Biopharma Launches Generic Zofran(R) in Canada, Expanding Oncology Supportive Care PortfolioAccesswire · Sep 24, 2026Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of nutritional supplements, primarily dedicating its efforts to the research and development of novel anticancer therapies. A key pipeline candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin, designed to combat a broad spectrum of malignancies, including leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, and liver cancers. Notably, Adva-27a also demonstrates efficacy against multidrug-resistant cancer cells, encompassing pancreatic, breast, small-cell lung, and uterine sarcoma cells.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 13, 2026 | -$1.20 | -$1.15 | Beat |
| May 13, 2026 | -$2.50 | -$2.50 | Beat |
| Apr 3, 2026 | -$2.70 | -$3.00 | Miss |
| Nov 13, 2025 | -$1.30 | -$1.90 | Miss |
| Aug 12, 2025 | -$1.10 | -$3.90 | Miss |
| May 15, 2025 | – | -$4.40 |